Literature DB >> 3510252

Natural cytotoxic effector cell activity against Shigella flexneri-infected HeLa cells.

G R Klimpel, D W Niesel, K D Klimpel.   

Abstract

Virus and facultative intracellular bacteria both replicate within a host cell. The recognition and killing of virus-infected cells by natural killer (NK) cells is thought to be an important host immune function. However, little is known about immune recognition of bacteria-infected cells. In this report, we show for the first time that human peripheral blood lymphocytes (PBL) and large granular lymphocytes (LGL) purified from PBL have significant levels of cytotoxic activity against Shigella flexneri-infected HeLa cells. This cytotoxic activity was dependent on bacterial invasion of the HeLa cells, because HeLa cells pretreated with a noninvasive isogenic variant of S. flexneri or soluble bacterial products were not killed. Pretreatment of PBL with interleukin 2 (IL 2) or interferon-alpha greatly enhanced the cytotoxic activity of PBL against Shigella-infected HeLa cells. Cytotoxic activity present in PBL or in PBL pretreated with IL 2 was shown to be associated with both Leu-11+ and Leu-11- cell populations. These results suggest that NK cell killing of bacteria-infected cells may play an important role in host defense against facultative intracellular bacterial infections.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3510252

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

1.  Natural killer cell-mediated lysis of Mycobacterium-avium complex-infected monocytes.

Authors:  P Katz; H Yeager; G Whalen; M Evans; R P Swartz; J Roecklein
Journal:  J Clin Immunol       Date:  1990-01       Impact factor: 8.317

2.  Peripheral blood lymphocytes from thermal injury patients are defective in their ability to generate lymphokine-activated killer (LAK) cell activity.

Authors:  G R Klimpel; D H Herndon; M D Stein
Journal:  J Clin Immunol       Date:  1988-01       Impact factor: 8.317

3.  Natural and recombinant interferons inhibit epithelial cell invasion by Shigella spp.

Authors:  D W Niesel; C B Hess; Y J Cho; K D Klimpel; G R Klimpel
Journal:  Infect Immun       Date:  1986-06       Impact factor: 3.441

4.  Interferon production by Shigella flexneri-infected fibroblasts depends upon intracellular bacterial metabolism.

Authors:  C B Hess; D W Niesel; J Holmgren; G Jonson; G R Klimpel
Journal:  Infect Immun       Date:  1990-02       Impact factor: 3.441

Review 5.  Natural killer (NK) cells in antibacterial innate immunity: angels or devils?

Authors:  Fernando Souza-Fonseca-Guimaraes; Minou Adib-Conquy; Jean-Marc Cavaillon
Journal:  Mol Med       Date:  2012-03-30       Impact factor: 6.354

6.  Leukocyte-mediated lysis of infected hepatocytes during listeriosis occurs in mice depleted of NK cells or CD4+ CD8+ Thy1.2+ T cells.

Authors:  J W Conlan; P L Dunn; R J North
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

7.  Secretory immunoglobulin A response following peroral priming and challenge with Shigella flexneri lacking the 140-megadalton virulence plasmid.

Authors:  D F Keren; R A McDonald; S B Formal
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

8.  Lack of a role for natural killer cells in early control of Brucella abortus 2308 infections in mice.

Authors:  D M Fernandes; R Benson; C L Baldwin
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

9.  Listeria monocytogenes activation of human peripheral blood lymphocytes: induction of non-major histocompatibility complex-restricted cytotoxic activity and cytokine production.

Authors:  Y Guo; D W Niesel; H K Ziegler; G R Klimpel
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.441

10.  Mycobacterium leprae renders Schwann cells and mononuclear phagocytes susceptible or resistant to killer cells.

Authors:  U Steinhoff; A Wand-Württenberger; A Bremerich; S H Kaufmann
Journal:  Infect Immun       Date:  1991-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.